

Olivier Blin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7248738/publications.pdf>

Version: 2024-02-01

114
papers

3,750
citations

136740

32
h-index

155451

55
g-index

130
all docs

130
docs citations

130
times ranked

6130
citing authors

#	ARTICLE	IF	CITATIONS
1	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. <i>Magnetic Resonance Imaging</i> , 2021, 76, 108-115.	1.0	24
2	RNA therapeutics for mood disorders: current evidence toward clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 721-736.	1.9	2
3	Development and Validation of a Simple and Rapid Ultrahigh-Performance Liquid Chromatography Tandem Spectrometry Method for the Quantification of Hydroxychloroquine in Plasma and Blood Samples in the Emergency Context of SARS-CoV-2 Pandemic. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 570-576.	1.0	7
4	Convergent and Discriminant Validity of Default Mode Network and Limbic Network Perfusion in Amnestic Mild Cognitive Impairment Patients. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 1797-1808.	1.2	4
5	Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2507-2519.	0.9	1
6	Polyaminosteroid Analogues as Potent Antibacterial Agents Against Mupirocin- Resistant <i>Staphylococcus aureus</i> Strains. <i>Anti-Infective Agents</i> , 2020, 18, 239-244.	0.1	1
7	CSF cutoffs for MCI due to AD depend on APOE ϵ 4 carrier status. <i>Neurobiology of Aging</i> , 2020, 89, 55-62.	1.5	11
8	Modular slowing of resting-state dynamic functional connectivity as a marker of cognitive dysfunction induced by sleep deprivation. <i>NeuroImage</i> , 2020, 222, 117155.	2.1	24
9	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.	1.2	7
10	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225.	1.2	13
11	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. <i>NeuroImage</i> , 2020, 218, 116932.	2.1	38
12	An Alzheimer Disease Challenge Model: 24-Hour Sleep Deprivation in Healthy Volunteers, Impact on Working Memory, and Reversal Effect of Pharmacological Intervention. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 222-230.	0.7	10
13	Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2319-2324.	1.1	3
14	Dynamic Functional Connectivity as a complex random walk: Definitions and the dFCwalk toolbox. <i>MethodsX</i> , 2020, 7, 101168.	0.7	14
15	Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 3-14.	1.2	18
16	Sleep deprivation and Modafinil affect cortical sources of resting state electroencephalographic rhythms in healthy young adults. <i>Clinical Neurophysiology</i> , 2019, 130, 1488-1498.	0.7	10
17	<i>Staphylococcus aureus</i> nasal decolonization strategies: a review. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 327-340.	2.0	34
18	One Step Forward Toward a Surrogate Endpoint for Clinical Trials of Alzheimer's Disease Drugs: The Results of PharmaCog WP5 (European ADNI). <i>Journal of Alzheimer's Disease</i> , 2019, 69, 1-2.	1.2	3

#	ARTICLE	IF	CITATIONS
19	Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 49-58.	1.2	8
20	Plasma A β 242 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 37-48.	1.2	23
21	Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 15-35.	1.2	34
22	Prolonged continuous wound infiltration with a local anaesthetic after total mastectomy: pharmacokinetics and preliminary results on postoperative pain. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2019, 38, 385-386.	0.6	1
23	A 15-day course of donepezil modulates spectral EEG dynamics related to target auditory stimuli in young, healthy adult volunteers. <i>Clinical Neurophysiology</i> , 2019, 130, 863-875.	0.7	5
24	Effect of desipramine on patients with breathing disorders in <scp>RETT</scp> syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 118-127.	1.7	15
25	Ropivacaine Wound Infiltration for Pain Management After Breast Cancer Mastectomy: A Population Pharmacokinetic Analysis. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 811-819.	0.8	4
26	Impaired cortico-limbic functional connectivity in schizophrenia patients during emotion processing. <i>Social Cognitive and Affective Neuroscience</i> , 2018, 13, 381-390.	1.5	17
27	Brain Networks are Independently Modulated by Donepezil, Sleep, and Sleep Deprivation. <i>Brain Topography</i> , 2018, 31, 380-391.	0.8	27
28	Perampanel-associated self-harm ideation after dosage increase. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 243-244.	0.8	3
29	Staphylococcus aureus Nasal Colonization: An Update on Mechanisms, Epidemiology, Risk Factors, and Subsequent Infections. <i>Frontiers in Microbiology</i> , 2018, 9, 2419.	1.5	303
30	Cannabis smoking impairs driving performance on the simulator and real driving: a randomized, double-blind, placebo-controlled, crossover trial. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 558-570.	1.0	34
31	Population pharmacokinetic model for tumescent lidocaine in women undergoing breast cancer surgery. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1309-1315.	0.8	2
32	Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies. <i>Clinical Pharmacokinetics</i> , 2017, 56, 127-138.	1.6	56
33	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). <i>Neurobiology of Aging</i> , 2017, 53, 1-10.	1.5	59
34	Phenobarbital in intensive care unit pediatric population: predictive performances of population pharmacokinetic model. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 558-566.	1.0	9
35	Childhood trauma and emotional processing circuits in schizophrenia: A functional connectivity study. <i>Schizophrenia Research</i> , 2017, 184, 69-72.	1.1	33
36	Neuropsychiatric events and dolutegravir in HIV patients. <i>Aids</i> , 2017, 31, 1775-1777.	1.0	18

#	ARTICLE	IF	CITATIONS
37	Long-term use of antipsychotics in community-dwelling dementia patients. <i>International Clinical Psychopharmacology</i> , 2017, 32, 13-19.	0.9	6
38	Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 685-694.	1.0	8
39	Comment on "Patient Reporting in the EU: Analysis of EudraVigilance Data". <i>Drug Safety</i> , 2017, 40, 935-936.	1.4	2
40	Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1039-1047.	1.1	12
41	Antidepressant adherence patterns in older patients: use of a clustering method on a prescription database. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 226-236.	1.0	11
42	Levodopa in Parkinson's Disease: A Review of Population Pharmacokinetics/Pharmacodynamics Analysis. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2017, 20, 226.	0.9	13
43	A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients. <i>PLoS ONE</i> , 2017, 12, e0169878.	1.1	10
44	Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in Occasional Cannabis Smokers After Smoking Cannabis Cigarette. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2016, 19, 411.	0.9	19
45	Simultaneous determination of four antiepileptic drugs in human plasma samples using an ultra-high performance liquid chromatography tandem mass spectrometry method and its application in therapeutic drug monitoring. <i>Biomedical Chromatography</i> , 2016, 30, 2053-2060.	0.8	17
46	Baseline CSF A β ₂ , A β ₂ /T-TAU and A β ₂ /P-tau distributions to classify pharmacog MCI patients. <i>Neurobiology of Aging</i> , 2016, 39, S30.	1.5	0
47	Relation between facial affect recognition and configural face processing in antipsychotic-free schizophrenia. <i>Neuropsychology</i> , 2015, 29, 197-204.	1.0	14
48	Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite European 3T study on healthy elderly. <i>Human Brain Mapping</i> , 2015, 36, 3516-3527.	1.9	34
49	Effect of trait anxiety on prefrontal control mechanisms during emotional conflict. <i>Human Brain Mapping</i> , 2015, 36, 2207-2214.	1.9	28
50	Acute stress disorder modifies cerebral activity of amygdala and prefrontal cortex. <i>Cognitive Neuroscience</i> , 2015, 6, 39-43.	0.6	19
51	CX3CR1 is dysregulated in blood and brain from schizophrenia patients. <i>Schizophrenia Research</i> , 2015, 168, 434-443.	1.1	49
52	Clinical spectrum and gender differences in a large cohort of Charcot-Marie-Tooth type 1A patients. <i>Journal of the Neurological Sciences</i> , 2014, 336, 155-160.	0.3	22
53	Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged <i>Octodon degus</i> . <i>Neuropharmacology</i> , 2014, 85, 206-214.	2.0	21
54	Telemedicine: What Framework, What Levels of Proof, Implementation Rules. <i>Therapie</i> , 2014, 69, 347-354.	0.6	2

#	ARTICLE	IF	CITATIONS
55	A Review of the Effects of Hypoxia, Sleep Deprivation and Transcranial Magnetic Stimulation on EEG Activity in Humans: Challenges for Drug Discovery for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2014, 11, 501-518.	0.7	18
56	Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease. <i>Current Medical Research and Opinion</i> , 2013, 29, 23-31.	0.9	21
57	Relationship between emotional experience and resilience: An fMRI study in fire-fighters. <i>Neuropsychologia</i> , 2013, 51, 845-849.	0.7	35
58	Brain morphometry reproducibility in multi-center 3T MRI studies: A comparison of cross-sectional and longitudinal segmentations. <i>NeuroImage</i> , 2013, 83, 472-484.	2.1	157
59	Synaptic function as a preclinical and experimental medicine readout for disease-modifying therapy in Alzheimer's Disease. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2013, 10, e99-e104.	0.5	2
60	Emotional Reactivity Assessment of Healthy Elderly with an Emotion-Induction Procedure. <i>Experimental Aging Research</i> , 2013, 39, 109-124.	0.6	8
61	Clinical innovation for neurodegenerative diseases. <i>Clinical Investigation</i> , 2012, 2, 663-665.	0.0	6
62	Voluntary Emotion Suppression Modifies Psychophysiological Responses to Films. <i>Journal of Psychophysiology</i> , 2012, 26, 116-123.	0.3	17
63	Neuroticism Modifies Psychophysiological Responses to Fearful Films. <i>PLoS ONE</i> , 2012, 7, e32413.	1.1	43
64	Attentional bias in post-traumatic stress disorder diminishes after symptom amelioration. <i>Behaviour Research and Therapy</i> , 2011, 49, 796-801.	1.6	49
65	Comparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: A Multiple-treatment Bayesian Metaanalysis. <i>Journal of Rheumatology</i> , 2011, 38, 835-845.	1.0	45
66	Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 753-761.	1.0	18
67	Amygdala activity correlates with attentional bias in PTSD. <i>Neuropsychologia</i> , 2011, 49, 1969-1973.	0.7	88
68	Effects of paroxetine on emotional functioning and treatment awareness: a 4-week randomized placebo-controlled study in healthy clinicians. <i>Psychopharmacology</i> , 2010, 207, 619-629.	1.5	5
69	Pure-tone auditory thresholds are decreased in depressed people with post-traumatic stress disorder. <i>Journal of Affective Disorders</i> , 2010, 127, 169-176.	2.0	10
70	Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo-controlled, randomized, double-blind, crossover study. <i>Movement Disorders</i> , 2010, 25, 368-376.	2.2	21
71	Differential patterns of initial and sustained responses in amygdala and cortical regions to emotional stimuli in schizophrenia patients and healthy participants. <i>Journal of Psychiatry and Neuroscience</i> , 2010, 35, 41-48.	1.4	24
72	Difficultés cliniques dans les maladies rares: comment les lever?. <i>Presse Medicale</i> , 2010, 39, 51-52.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Dopaminergic modulation of the default mode network in Parkinson's disease. <i>European Neuropsychopharmacology</i> , 2010, 20, 784-792.	0.3	105
74	Effect of ascorbic acid in patients with Charcotâ€“Marieâ€“Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2009, 8, 1103-1110.	4.9	114
75	Cognitive impulsivity in Parkinson's disease patients: Assessment and pathophysiology. <i>Movement Disorders</i> , 2009, 24, 2316-2327.	2.2	32
76	Effects of dimethylaminoethanol pyroglutamate (DMAE p-Glu) against memory deficits induced by scopolamine: evidence from preclinical and clinical studies. <i>Psychopharmacology</i> , 2009, 207, 201-212.	1.5	12
77	Hemodynamic, autonomic and baroreflex changes after one night sleep deprivation in healthy volunteers. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2009, 145, 76-80.	1.4	49
78	Risperidone versus haloperidol for facial affect recognition in schizophrenia: Findings from a randomised study. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 719-728.	1.3	25
79	Dopaminergic Modulation of Amygdala Activity During Emotion Recognition in Patients With Parkinson Disease. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 548-554.	0.7	37
80	Analysis of the benefits of vitamin cocktails in treating Charcotâ€“Marieâ€“Tooth disease type 1A. <i>Muscle and Nerve</i> , 2008, 38, 1052-1054.	1.0	10
81	Neural bases of different cognitive strategies for facial affect processing in schizophrenia. <i>Schizophrenia Research</i> , 2008, 100, 191-205.	1.1	129
82	Evidence of a Decrease in Heart Rate and Skin Conductance Responses in PTSD Patients After a Single EMDR Session. <i>Journal of EMDR Practice and Research</i> , 2008, 2, 51-56.	0.2	32
83	Amygdala Activation Modulated by Levodopa During Emotional Recognition Processing in Healthy Volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 692-697.	0.7	24
84	Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. <i>Neuromuscular Disorders</i> , 2007, 17, 248-253.	0.3	67
85	Use of albumin in three French university hospitals: is prescription monitoring still useful in 2004?. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 79-85.	0.9	8
86	Influence of visual cues on gait in Parkinson's disease: Contribution to attention or sensory dependence?. <i>Journal of the Neurological Sciences</i> , 2006, 248, 192-195.	0.3	125
87	Erratum. <i>Clinical Neuropharmacology</i> , 2006, 29, 185.	0.2	15
88	A Double-blind, Placebo- and Flurazepam-controlled Investigation of the Residual Psychomotor and Cognitive Effects of Modified Release Zolpidem in Young Healthy Volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 284-289.	0.7	29
89	Brain T1 intensity changes after levodopa administration in healthy subjects: a voxel-based morphometry study. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 546-551.	1.1	36
90	Dopaminergic Contribution to the Regulation of Emotional Perception. <i>Clinical Neuropharmacology</i> , 2005, 28, 228-237.	0.2	121

#	ARTICLE	IF	CITATIONS
91	Pergolide. <i>Clinical Neuropharmacology</i> , 2005, 28, 120-125.	0.2	14
92	Effect of Levodopa on Healthy Volunteers' Facial Emotion Perception. <i>Clinical Neuropharmacology</i> , 2005, 28, 255-261.	0.2	38
93	An additive factor analysis of the effect of depression on the reaction time of old patients. <i>Acta Psychologica</i> , 2004, 117, 1-11.	0.7	22
94	A study of a topiramate pre-treatment on the effects induced by a subanaesthetic dose of ketamine on human reaction time. <i>Neuroscience Letters</i> , 2004, 369, 99-103.	1.0	5
95	An electromyographic analysis of the effect of levodopa on the response time of healthy subjects. <i>Psychopharmacology</i> , 2003, 165, 313-316.	1.5	16
96	Risk propensity in commercial and military pilots. <i>Aviation, Space, and Environmental Medicine</i> , 2003, 74, 879-81.	0.6	8
97	Effects of Subanesthetic Doses of Ketamine on Sensorimotor Information Processing in Healthy Subjects. <i>Clinical Neuropharmacology</i> , 2002, 25, 101-106.	0.2	24
98	Dopamine and human information processing: a reaction-time analysis of the effect of levodopa in healthy subjects. <i>Psychopharmacology</i> , 2002, 163, 62-67.	1.5	39
99	N-methyl-D-aspartate receptors and information processing: human choice reaction time under a subanaesthetic dose of ketamine. <i>Neuroscience Letters</i> , 2001, 303, 29-32.	1.0	22
100	Neurobiology and Clinical Pharmacology of Obsessive-Compulsive Disorder. <i>Clinical Neuropharmacology</i> , 2001, 24, 191-207.	0.2	68
101	Levodopa-induced Drowsiness in Healthy Volunteers: Results of a Choice Reaction Time Test Combined with a Subjective Evaluation of Sedation. <i>Clinical Neuropharmacology</i> , 2001, 24, 91-94.	0.2	20
102	Pharmacokinetic and Pharmacodynamic Analysis of Sedative and Amnesic Effects of Lorazepam in Healthy Volunteers. <i>Clinical Neuropharmacology</i> , 2001, 24, 71-81.	0.2	34
103	Controlled Trial of 3-Day Quinine-Clindamycin Treatment versus 7-Day Quinine Treatment for Adult Travelers with Uncomplicated Falciparum Malaria Imported from the Tropics. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 932-935.	1.4	40
104	Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorption of IS-159, a peptide serotonin 1B/1D-receptor agonist. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 114-121.	2.3	9
105	Effects of Lorazepam on Emotional Reactivity, Performance, and Vigilance in Subjects With High or Low Anxiety. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 226-233.	0.7	8
106	Serotonin and human information processing: an electromyographic study of the effects of fluvoxamine on choice reaction time. <i>Neuroscience Letters</i> , 1999, 265, 143-146.	1.0	15
107	A Comparative Review of New Antipsychotics. <i>Canadian Journal of Psychiatry</i> , 1999, 44, 235-244.	0.9	98
108	Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. <i>European Neuropsychopharmacology</i> , 1997, 7, 125-137.	0.3	247

#	ARTICLE	IF	CITATIONS
109	Serotonin and human information processing: fluvoxamine can improve reaction time performance. <i>Neuroscience Letters</i> , 1997, 229, 204-208.	1.0	56
110	Antipsychotic and Anxiolytic Properties of Risperidone, Haloperidol, and Methotrimeprazine in Schizophrenic Patients. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 38-44.	0.7	100
111	Contrast sensitivity improvement with sulfamethoxazole and trimethoprim in a patient with Machado-Joseph disease without spasticity. <i>Journal of the Neurological Sciences</i> , 1994, 123, 95-99.	0.3	9
112	Low luminance contrast sensitivity: Effects of training on psychophysical and optokinetic nystagmus thresholds in man. <i>Vision Research</i> , 1994, 34, 1893-1899.	0.7	5
113	A comparison between the effect of intentional modulations and the action of l-Dopa on gait in Parkinson's disease. <i>Behavioural Brain Research</i> , 1991, 45, 177-183.	1.2	42
114	Apomorphine-Induced Yawning in Migraine Patients. <i>Clinical Neuropharmacology</i> , 1991, 14, 91.	0.2	49